Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Floxuridine

Floxuridine: 1 brand, 3 generics; first approved Apr 16, 2000; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available: 3 ANDA applications approved.

Brands (NDA)
1
Generics (ANDA)
3
Listed patents
0
Presentations
4

Brand (NDA) products

Originator applications
  • FUDRRLD
    NDA 016929
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    500MG/VIALINJECTABLEINJECTIONDiscontinued

Generic (ANDA) products (3)

Abbreviated applications
  • FLOXURIDINE
    ANDA 2030082017
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    500MG/VIALINJECTABLEINJECTIONDiscontinued
  • FLOXURIDINE
    ANDA 0758372001
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    500MG/VIALINJECTABLEINJECTIONRxAP
  • FLOXURIDINERS
    ANDA 0753872000
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    500MG/VIALINJECTABLEINJECTIONRxAP

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
First approval
26 yr 9 mo ago
Most recent approval
8 yr 11 mo ago

Approvals span 2000–2017 across 4 FDA applications.

Brand (NDA) 125%
Generic (ANDA) 375%

Floxuridine: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.